Aethlon Medical has enrolled the first two patients in its Hemopurifier cancer trial at Royal Adelaide Hospital, Australia. A second site, Pindara Private Hospital, is now open for enrollment. The company received ethics approval for a similar trial in India.For Q2 FY2024 ended September 30, Aethlon reported a net loss of $2.8 million, down from $3.0 million in Q2 FY2023. Operating expenses decreased 9% to $2.9 million. Cash balance stood at $6.9 million as of September 30, 2024.The company implemented cost-cutting measures to focus resources on its oncology trials. James Frakes was appointed permanent CEO in October. Aethlon continues to explore the Hemopurifier's potential for treating viral infections alongside its primary focus on cancer therapy.

Aethlon Medical has enrolled the first two patients in its Hemopurifier cancer trial at Royal Adelaide Hospital, Australia. A second site, Pindara Private Hospital, is now open for enrollment. The company received ethics approval for a similar trial in India.For Q2 FY2024 ended September 30, Aethlon reported a net loss of $2.8 million, down from $3.0 million in Q2 FY2023. Operating expenses decreased 9% to $2.9 million. Cash balance stood at $6.9 million as of September 30, 2024.The company implemented cost-cutting measures to focus resources on its oncology trials. James Frakes was appointed permanent CEO in October. Aethlon continues to explore the Hemopurifier's potential for treating viral infections alongside its primary focus on cancer therapy.